RephImmune, led by a skilled team with deep cell therapy experience, including experts with FDA-approved product credentials, is committed to advancing innovative cell and gene therapies. Our primary focus is on immune cell engineering therapies for solid tumor treatment. Our strategy leverages engineered cell tech, addressing constraints of conventional CAR-T methods. Our therapy's superior efficacy and outstanding tumor eradication abilities set it apart from conventional CAR-T approaches. We firmly believe that our pioneering achievements will shape the future landscape of cell therapy in the field of solid tumor treatment.